Key strategies adopted by these players include the development of advanced therapies, mergers and acquisitions, and investment in R&D to enhance diabetic and chronic weight management solutions and meet growing global demand
10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association

Reported Issues: Consumers report: That the supplement did not lead to weight loss or appetite suppression as advertised That the product was marketed using misleading claims about GLP-1 support That they paid for a product that did not provide the promised benefits That the supplements are promoted as alternatives to GLP-1 medications, despite not functioning like prescription GLP-1 drugs That marketing materials imply that these supplements are scientifically and medically proven and reliable, when evidence may be lacking That they would not have purchased the supplements if they had known the claims were not supported by reliable scientific evidence Experiencing adverse side effects such as stomach pain, nausea, or weight gain Why Individuals Should Be Concerned: Potential claims include: Economic loss Safety risk False advertising Product defect Performance vs
Even if your insurance covers the bulk of the expenses, you may have to jump through prior authorization hoops